CGM
BMY icon

Capital Growth Management’s Bristol-Myers Squibb BMY Stock Holding History

Capital Growth Management’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-120,000
Closed -$9.24M – 55
2022
Q2 		$9.24M Buy
+120,000
New +$9.14M 1.1% 31

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Growth Management's BMY Position: Q3 2022 in Review

Capital Growth Management sold out of Bristol-Myers Squibb (BMY) in Q3 2022, closing a stake of 120,000 shares — an estimated $9.24M sold.

Capital Growth Management first reported a position in BMY in Q2 2022 and held it in 1 quarter. The position peaked at $9.24M in Q2 2022. 2,470 funds tracked by Wall St. Rank hold BMY as of Q3 2022.

  • Capital Growth Management reported no remaining Bristol-Myers Squibb position as of Q3 2022 after selling out during the quarter.
  • Capital Growth Management sold 120,000 Bristol-Myers Squibb shares in Q3 2022, an estimated $9.24M.
  • Capital Growth Management first reported a position in Bristol-Myers Squibb in Q2 2022 and held it in 1 quarter.
  • Capital Growth Management's Bristol-Myers Squibb position peaked at $9.24M in Q2 2022.
  • 2,470 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2022.

Based on Capital Growth Management's 13F filing for Q3 2022, filed 14 Nov 2022.